Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Tendenze

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

EasyMarkets
Dati di Mercato
Notizie
Utensili
Mertcato
Scoprire
Premium Login/Registrati
Ftse Mib
28.243,26
(
0,28%
)
S&P 500
4.288,05
(
-0,27%
)
US Tech 100
14.344,00
(
0,16%
)
Dow Jones
33.507,50
(
-0,47%
)
Bitcoin
27.142,35
(
0,67%
)
  1. Home
  2. Investire
  3. Azioni
  4. Europa
  5. EU
  6. Hyloris Pharmaceuticals SA (HYL)

  7. Hyloris Pharmaceuticals SA (HYL) Notizie

HYL

Hyloris Pharmaceuticals (HYL)

Hyloris Pharmaceuticals SA
Da:
Ordina per:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:HYL
DataOraFonteTitoloSimboloCompagnia
06/09/202322:00GlobeNewswire Inc.Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook EU:HYLHyloris Pharmaceuticals SA
06/09/202322:00GlobeNewswire Inc.Hyloris Pharmaceuticals présente ses résultats semestriels pour 2023 et ses perspectives d'activité EU:HYLHyloris Pharmaceuticals SA
22/06/202307:00GlobeNewswire Inc.Hyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura(TM) EU:HYLHyloris Pharmaceuticals SA
22/06/202307:00GlobeNewswire Inc.Hyloris annonce le recrutement d’un premier patient pour son essai clinique à 4 bras concernant Alenura(TM) EU:HYLHyloris Pharmaceuticals SA
13/06/202317:59GlobeNewswire Inc.Les actionnaires d’Hyloris adoptent toutes les résolutions de l’Assemblée Générale Annuelle EU:HYLHyloris Pharmaceuticals SA
13/06/202317:59GlobeNewswire Inc.Hyloris shareholders approve all resolutions at the Annual General Meeting EU:HYLHyloris Pharmaceuticals SA
08/06/202317:59GlobeNewswire Inc.Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region EU:HYLHyloris Pharmaceuticals SA
08/06/202317:59GlobeNewswire Inc.Hyloris Pharmaceuticals perçoit 1 million € de financement non dilutif de la Région Wallonne EU:HYLHyloris Pharmaceuticals SA
02/05/202307:00GlobeNewswire Inc.Hyloris announces potential registration date for Maxigesic® IV in the US EU:HYLHyloris Pharmaceuticals SA
02/05/202307:00GlobeNewswire Inc.Hyloris annonce une date potentielle d’enregistrement pour Maxigesic® IV aux Etats-Unis EU:HYLHyloris Pharmaceuticals SA
28/04/202307:00GlobeNewswire Inc.Hyloris publie son rapport annuel 2022 et ses objectifs ESG EU:HYLHyloris Pharmaceuticals SA
28/04/202307:00GlobeNewswire Inc.Hyloris releases Annual Report 2022, including ESG objectives EU:HYLHyloris Pharmaceuticals SA
18/04/202307:00GlobeNewswire Inc.Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA EU:HYLHyloris Pharmaceuticals SA
18/04/202307:00GlobeNewswire Inc.Hyloris annonce la soumission des données relatives au conditionnement de Maxigesic® IV demandées par la FDA aux Etats-Unis EU:HYLHyloris Pharmaceuticals SA
15/03/202319:03GlobeNewswire Inc.Hyloris présente ses résultats annuels pour 2022 et ses perspectives d’avenir EU:HYLHyloris Pharmaceuticals SA
15/03/202319:03GlobeNewswire Inc.Hyloris reports full year results for 2022 & provides business outlook EU:HYLHyloris Pharmaceuticals SA
24/01/202307:00GlobeNewswire Inc.Hyloris annonce un partenariat commercial pour Maxigesic® IV dans 9 pays européens EU:HYLHyloris Pharmaceuticals SA
24/01/202307:00GlobeNewswire Inc.Hyloris Announces Commercial Partnership for Maxigesic® IV in 9 European Countries EU:HYLHyloris Pharmaceuticals SA
20/01/202307:00GlobeNewswire Inc.Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood (hypophosphatemia) EU:HYLHyloris Pharmaceuticals SA
20/01/202307:00GlobeNewswire Inc.Hyloris Pharmaceuticals élargit son portefeuille avec un produit candidat pour le traitement de la déficience minérale dans le sang (l’hypophosphatémie) EU:HYLHyloris Pharmaceuticals SA
22/11/202218:00GlobeNewswire Inc.Hyloris Pharmaceuticals Elargit son Portefeuille de Produits avec un Spray Nasal pour la Rhinite Idiopathique EU:HYLHyloris Pharmaceuticals SA
22/11/202218:00GlobeNewswire Inc.Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis EU:HYLHyloris Pharmaceuticals SA
12/10/202216:00GlobeNewswire Inc.Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainable Growth Strategy and Support of Social Well-Being for its Employees EU:HYLHyloris Pharmaceuticals SA
12/10/202216:00GlobeNewswire Inc.Hyloris Pharmaceuticals Annonce son Déménagement sur le Site du LégiaPark, conformément à sa Stratégie de Croissance Durable et au Bien-Etre Social de ses Employés EU:HYLHyloris Pharmaceuticals SA
01/09/202207:00GlobeNewswire Inc.Hyloris Pharmaceuticals annonce ses résultats semestriels pour 2022 et présente une mise à jour de ses activités EU:HYLHyloris Pharmaceuticals SA
01/09/202207:00GlobeNewswire Inc.Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update EU:HYLHyloris Pharmaceuticals SA
20/07/202207:00GlobeNewswire Inc.Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures EU:HYLHyloris Pharmaceuticals SA
20/07/202207:00GlobeNewswire Inc.Hyloris présente des données positives pour la phase 1 de HY-004, un Acide Tranexamique Oral - Rinçage Buccal exclusif indiqué dans les saignements liés aux interventions dentaires EU:HYLHyloris Pharmaceuticals SA
01/07/202220:00GlobeNewswire Inc.Hyloris Provides Additional Information on U.S. FDA Review of NDA Application for the Registration of Maxigesic IV® EU:HYLHyloris Pharmaceuticals SA
01/07/202209:55GlobeNewswire Inc.US FDA seeks more information on Maxigesic IV® application EU:HYLHyloris Pharmaceuticals SA
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:HYL
La tua Cronologia
BIT
BMPS
Monte Pasc..
BITI
FTSEMIB
FTSE Mib
BIT
UCG
Unicredit
NASDAQ
AAPL
Apple
FX
EURUSD
Euro vs Do..
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.

Registrati ora per creare la tua watchlist personalizzata in tempo reale streaming.

Accedi a ADVFN
Registrati ora
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

Support: +39 02 3045 3014 | support@advfn.it

V: it D: 20231001 08:36:16